Amyloidosis Center News

66th Annual Meeting of American Society of Hematology

Dr Sanchorawala discusses new research presented at the 66th Annual Meeting of American Society of Hematology in San Diego, CA in December 2024. https://www.vjhemonc.com/event/amyloidosis-sessions-highlights-from-ash-2024/

In Memoriam: Dr. Lawreen Connors

October 20, 2024 It is with profound sadness that we announce the passing of our dear colleague, Dr. Lawreen Connors, on October 20, 2024. Lawreen was a cornerstone of the Amyloidosis Center for many years, renowned not only for her groundbreaking research but also for her generosity, mentorship, and collaborative spirit. More

Vutrisiran in Patients with Transthyretin Amyloidosis with Cardiomyopathy

The HELIOS B trial, recently published in NEJM, has unveiled promising results for patients with ATTR amyloidosis with cardiomyopathy (ATTR-CM). Vutrisiran, a cutting-edge siRNA therapy, significantly reduced the risk of death and cardiac events compared to placebo. Over 36 months, Vutrisiran also showed improvements in walking distance and quality of... More

ISA 2024 Report

Click here to view a synopsis of the BU Amyloidosis Center's attendance at the International Symposium on Amyloidosis at the Mayo Clinic May 26-30, 2024.

How Well Are You Managing Transthyretin Amyloidosis (ATTR)?

https://url.us.m.mimecastprotect.com/s/CIYtCzp59jCkoYkKh4FCbx?domain=everydayhealth.com/ An article for Everyday Health about managing transthyretin amyloidosis, lifestyle habits, treatment, medication, and complications with our very own Lisa Mendelson, NP. 

2024 Webinar: ATTR Cardiac Amyloidosis

What's new and exciting in ATTR cardiac amyloidosis in 2024 Dr. Fredrick Ruberg and Dr. Omar Siddiqi discuss the general overview of ATTR treatment with new developments over the past year (APOLLO-B, ATTRibute-CM), currently enrolled trials (HELIOS-B, CARDIOTTRansform), and future trials (DepleTTR-CM, MAGNITUDE). They will also cover current heart failure therapy... More